TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2028-11-30
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, open-label, Phase III clinical trial which compares the
safety and efficacy of TGRX-326 with crizotinib in patients with ALK-positive advanced or
metastatic NSCLC